Sutro Biopharma (NASDAQ:STRO) Issues Earnings Results, Misses Estimates By $0.14 EPS

Sutro Biopharma (NASDAQ:STRO) posted its quarterly earnings data on Wednesday. The company reported ($2.33) earnings per share for the quarter, missing the consensus estimate of ($2.19) by ($0.14), FiscalAI reports. The business had revenue of $9.84 million for the quarter, compared to analysts’ expectations of $11.96 million.

Sutro Biopharma Price Performance

Sutro Biopharma stock opened at $21.31 on Friday. Sutro Biopharma has a fifty-two week low of $7.15 and a fifty-two week high of $43.85. The firm has a market cap of $353.11 million, a price-to-earnings ratio of -1.93 and a beta of 1.55. The firm has a fifty day moving average price of $26.98 and a two-hundred day moving average price of $25.99.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of STRO. State of Tennessee Department of Treasury bought a new stake in shares of Sutro Biopharma in the fourth quarter valued at approximately $86,000. Opaleye Management Inc. bought a new position in Sutro Biopharma during the fourth quarter worth $2,206,000. Balyasny Asset Management L.P. bought a new position in Sutro Biopharma during the fourth quarter worth $2,662,000. ADAR1 Capital Management LLC acquired a new position in Sutro Biopharma during the 4th quarter valued at $776,000. Finally, Jane Street Group LLC bought a new stake in Sutro Biopharma in the 4th quarter valued at $265,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $60 price target, while HC Wainwright reiterated its “Buy” rating and $50 target. These targets imply substantial potential upside if Sutro’s pipeline advances successfully. Benzinga analyst coverage
• Positive Sentiment: HC Wainwright improved its longer-term loss forecasts for fiscal 2027 through 2030. Estimated losses were narrowed to $4.69 per share for 2027, $7.07 for 2028, $4.94 for 2029 and $5.09 for 2030, suggesting expectations for better future operating performance than previously modeled.
• Neutral Sentiment: Citizens JMP lowered its price target from $41 to $34 but retained a “Market Outperform” rating. The reduced target reflects more cautious valuation assumptions, although the firm still sees meaningful upside from current levels. Citizens JMP price target update
• Negative Sentiment: HC Wainwright lowered its projected third- and fourth-quarter 2026 losses to $2.38 and $2.46 per share, respectively, compared with prior estimates of $2.32 for each quarter. The revisions indicate higher expected near-term expenses and extend the company’s path to profitability.
• Negative Sentiment: Sutro’s recent quarterly results missed expectations, with a loss of $2.33 per share versus the $2.19 consensus estimate and revenue of $9.84 million versus estimates of $11.96 million. The company’s clinical update on the STRO-004 Phase 1 study also raised investor concerns, contributing to selling pressure. Why Sutro Biopharma stock is falling

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Wednesday, August 5th. Barclays began coverage on Sutro Biopharma in a research report on Thursday, May 28th. They set an “overweight” rating and a $56.00 price target on the stock. Citigroup reissued a “market outperform” rating on shares of Sutro Biopharma in a research note on Thursday. HC Wainwright raised their price target on shares of Sutro Biopharma from $28.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Finally, Citizens Jmp lowered their target price on Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $47.30.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.